Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | FABP6 | P51161 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17563260 | 0.85 | HCAR3 (0.45) | POLBSMN1; SMN2HCAR3LMNAKDM4E | |
| SCHEMBL19911299 | 0.82 | POLB (0.54) | POLBSMN1; SMN2LMNAKDM4ERAB9A | |
| SCHEMBL18762227 | 0.79 | TDP1 (0.46) | POLBSMN1; SMN2HCAR3LMNAKDM4E | |
| SCHEMBL12747298 | 0.78 | HCAR3 (0.49) | POLBSMN1; SMN2HCAR3KDM4ERAB9A | |
| SCHEMBL14726018 | 0.78 | HCAR3 (0.49) | POLBSMN1; SMN2HCAR3KDM4ERAB9A | |
| SCHEMBL12464366 | 0.78 | HCAR3 (0.53) | POLBSMN1; SMN2HCAR3KDM4ERAB9A | |
| SCHEMBL11396992 | 0.77 | RAB9A (0.61) | POLBSMN1; SMN2HCAR3KDM4ERAB9A | |
| SCHEMBL7732282 | 0.77 | RAB9A (0.50) | SMN1; SMN2HCAR3KDM4ERAB9ANPC1 | |
| SCHEMBL19014233 | 0.77 | HCAR3 (0.44) | POLBSMN1; SMN2HCAR3KDM4ERAB9A | |
| SCHEMBL18937427 | 0.76 | FGFR1 (0.51) | SMN1; SMN2HCAR3KDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2022115879-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| EP-3467930-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20180222856-A1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | VILNIUS UNIVERSITY (LT) | 2018-08-09 | — | — | US | disclosed |
| US-9220710-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-4460709-A | Process for producing oxygen-containing organic compounds | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1984-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | POLB 1747/4885SMN1; SMN2 3500/4885HCAR3 3562/4885 |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | POLB 4315/4885SMN1; SMN2 3273/4885HCAR3 1848/4885 |
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | DPYD, TP53, GLS | POLB 37/4885SMN1; SMN2 2183/4885HCAR3 2164/4885 |
| US-20180222856-A1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | CA9, CA2, CA7 | POLB 1960/4885SMN1; SMN2 1259/4885HCAR3 1707/4885 |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | POLB 118/4885SMN1; SMN2 3476/4885HCAR3 4636/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | POLB 1747/4885SMN1; SMN2 3500/4885HCAR3 3562/4885 |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | POLB 905/4885SMN1; SMN2 532/4885HCAR3 4667/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | POLB 1747/4885SMN1; SMN2 3500/4885HCAR3 3562/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | POLB 4269/4885SMN1; SMN2 3347/4885HCAR3 2588/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | POLB 1747/4885SMN1; SMN2 3500/4885HCAR3 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.